The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial
Abstract
Summary: In patients with atrial fibrillation (AF) who require interruption of dabigatran or warfarin for an elective surgery/procedure, the risks and benefits of perioperative bridging anticoagulation is uncertain. We accessed the database from RE-LY, a randomised trial comparing dabigatran with warfarin for stroke prevention in AF, to assess the potential benefits and risks of bridging. In patients who had a first interruption of dabigatran or warfarin for an elective surgery/procedure, we compared the risk for major bleeding (MB), stroke or systemic embolism (SSE) and any thromboembolism (TE) in patients who were bridged or not bridged during the period of seven days before until 30 days after surgery/procedure. We used multivariable Cox regression to adjust for potential confounders. Bridging was used more during warfarin interruption than dabigatran interruption (27.5 % vs 15.4 %; p < 0.001). With dabigatran interruption, bridged patients had more MB (6.5 % vs 1.8 %, p < 0.001) than those not bridged but bridged and not bridged groups did not differ for any TE (1.2 % vs 0.6 %, p=0.16) and SSE (0.5 % vs 0.3 %, p=0.46). With warfarin interruption, bridged patients had more MB (6.8 % vs 1.6 %, p < 0.001) and any TE (1.8 % vs 0.3 %, p=0.007) than those not bridged but bridged and not bridged groups did not differ for SSE (0.5 % vs 0.2 %, p=0.321). In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/ procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719 · cited 1×
“It also is possible that the association between bridging and TE was due to an intervening episode of MB, which would delay resumption of anticoagulation and increase exposure to TE risk (25, 26).”
Background
Cited by
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Douketis, J. D., Spyropoulos, A. C., Kaatz, S., Becker, R. C., Caprini, J. A., Dunn, A. S., Garcia, D. A., Jacobson, A., Jaffer, A. K., Kong, D. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501035 · Cited by 1,184
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
Douketis, J. D., Spyropoulos, A. C., Duncan, J., Carrier, M., Le Gal, G., Tafur, A. J., Vanassche, T., Verhamme, P., Shivakumar, S., Gross, P. L., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2431 · Cited by 532
Self-citationPerioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Murad, M. H., Arcelus, J. I., Dager, W. E., Dunn, A. S., Fargo, R. A., Levy, J. H., Samama, C. M., Shah, S. H., et al. (2022) · CHEST · doi:10.1016/j.chest.2022.07.025 · Cited by 450
Self-citationDoherty, J. U., Gluckman, T. J., Hucker, W. J., Januzzi, J. L., Ortel, T. L., Saxonhouse, S. J., & Spinler, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.024 · Cited by 441
Oakland, K., Chadwick, G., East, J. E., Guy, R., Humphries, A., Jairath, V., McPherson, S., Metzner, M., Morris, A. J., Murphy, M. F., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317807 · Cited by 324
Metadata
- Authors
- Healey, J. S., Brueckmann, M., Eikelboom, J. W., Ezekowitz, M. D., Fraessdorf, M., Noack, H., Oldgren, J., Reilly, P., Spyropoulos, A. C., Wallentin, L., Connolly, S. J., & Douketis, J. D.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015-05
- Volume
- 113
- Issue
- 03
- Pages
- 625-632
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1939082786
- Cited by
- 231
- References
- 6
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial. https://app.cochat.ai/papers/10.1160/th14-04-0305
- The paper
- Healey, J. S., Brueckmann, M., Eikelboom, J. W., Ezekowitz, M. D., Fraessdorf, M., Noack, H., Oldgren, J., Reilly, P., Spyropoulos, A. C., Wallentin, L., Connolly, S. J., & Douketis, J. D. (2015). Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure: Substudy of the RE-LY trial. Thrombosis and Haemostasis. https://doi.org/10.1160/th14-04-0305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.